Clinical trial
Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia…
NCT00440726 · Therapeutic Advances in Childhood Leukemia Consortium, Other · Completed
Key facts
| NCT number | NCT00440726 |
|---|---|
| Title | Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL) |
| Official title | A Study of Bortezomib With Chemotherapy for Relapsed/Refractory Acute Lymphoblastic Leukemia |
| Lead sponsor | Therapeutic Advances in Childhood Leukemia Consortium, Other |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Acute Lymphoblastic Leukemia |
| Intervention type | Drug |
| Interventions | Bortezomib, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, Methotrexate, Vincristine, Triple IT Therapy |
| Enrollment | 31 |
| Start date | Aug 4, 2006 |
| Primary completion | Feb 26, 2011 |
| Completion | Feb 26, 2011 |
| First posted | Feb 27, 2007 |
| Last update posted | Feb 19, 2020 |
| Countries | Australia, Brazil, Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: